Key facts
- Dreampath Diagnostics’s last known valuation is $31.8M (Jun 2025).
- It has raised $3.1M; the latest was PE Growth/Expansion ($2.3M) in Jun 2025.
- Notable investors include Summit Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Dreampath Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Dreampath Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dreampath Diagnostics
Developer of laboratory diagnostics devices designed to protect patient samples and improve laboratory workflow. The company develops a fully automated traceable sample management and digital archiving services for pathology, to accelerate diagnosis and research, thereby helping patients and their families with treatment journeys and secure the diagnosis and development of personalized healthcare.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2011
- Employees
- 43
- Website
- dreampathdx.net/
- Ownership
- Privately Held (backing)
Dreampath Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dreampath Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dreampath Diagnostics in its N-PORT filings yet. We sweep new filings monthly.